

Janet T. Mills
Governor

Sara Gagné-Holmes
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, November 4, 2025
Time: 1:00 PM – 5:30 PM
Location: **Virtual:**
To Dial in: 1-207-209-4724
Phone Conference ID: 53322743#
Teams link: [Join the meeting now](#)

In-Person:
109 Capitol Street
11 State House Station Rooms A and B
Augusta, Maine 04333

CLOSED SESSION (1:00 PM – 2:30 PM)

Board members only (Invitations for Closed and Open Sessions Will Be Sent Separately)

OPEN SESSION (2:30 PM – 5:00 PM)

- 1) MaineCare Updates – Dan Mickool R.Ph, M.S., EdD, Associate Director of Pharmacy
- 2) Public Comments
- 3) Old Business
- 4) Consent Agenda
 - Approve September 9, 2025, Meeting Minutes
 - Revised Clinical Criteria
- 5) New Business
 - Present 2026 Meeting Schedule
 - March 10, 2026; June 9, 2026; September 8, 2026; and December 8, 2026
 - November 3, 2026 (Annual Meeting)
 - Present 2026 Retro DUR Potential Initiatives
 - Introduce 2026 Potential RetroDUR Initiatives
 - Review categories subject to potential changes. Additional categories without changes in 2026 from 2025 will not be reviewed and will not be voted on. Products will remain in their current Preferred or Non-Preferred status for the upcoming 2026 MaineCare PDL.

- Antiasthmatic – Anti-inflammatory Agents
- Anticonvulsants
- Antineoplastics – Biosimilar PDL
- Antipsychotic – LAI/Atypicals
- Bronchodilators, Beta Agonists
- Cytokine and CAM Antagonists
- Derm Atopic Dermatitis
- DME – Diabetic Supplies
- Epinephrine
- GI-Bowel Prep
- Growth Hormones
- Hematopoietics/CSF/ESA
- Hemophilia
- Humira – Biosimilar PDL
- Hyperammonia
- Hypoglycemics, Incretin Memetics
- Hypoglycemics, Insulins & Related Agents
- Hypoglycemics, SGLT2 Inhibitor & Misc. Agents
- Migraine
- Movement Disorders
- Multiple Sclerosis Agents
- Muscular Dystrophy Corticosteroids
- Ophthalmic Anti-inflammatories
- Opiate Dependence & Overdose Treatments
- Resp. Anticholinergic/Asthma/COPD/Steroid/Misc.
- Sick Cell Disease Agents
- Stelara – Biosimilar PDL
- Stimulants & Related Agents
- Uterine Fibroids
- Vaginal Anti-infectives

6) FDA Safety Alerts

- *Caprelsa Risk Removed: [FDA removes risk evaluation and mitigation strategies for Caprelsa \(vandetanib\)](#) – September 25, 2025*
- *Autism and Acetaminophen: [FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy](#) – September 22, 2025*

7) Next Meeting will be held on Tuesday, December 9, 2025

8) Adjournment: 5:00 PM